THERAFLU WARMING RELIEF FLU AND SORE THROAT OTC
Generic Name and Formulations:
Acetaminophen 325mg, diphenhydramine HCl 12.5mg, phenylephrine HCl 5mg; per 15mL; liq; contains potassium 5mg/15mL, sodium 7mg/15mL; cherry flavor.
Novartis Consumer Health
Indications for THERAFLU WARMING RELIEF FLU AND SORE THROAT :
Minor aches and pains. Headache. Fever. Sneezing. Rhinorrhea. Nasal and sinus congestion. Itchy eyes, nose, throat. Sore throat.
30mL every 4 hours. Max 180mL/24hrs.
During or within 14 days of MAOIs. Concomitant other acetaminophen, diphenhydramine (including skin) products.
Liver disease. Heart disease. Hypertension. Thyroid disease. Diabetes. Glaucoma. COPD. Asthma. GI or GU obstuction. Pregnancy. Nursing mothers.
Analgesic + antihistamine + sympathomimetic.
See Contraindications. Hypertensive crisis with MAOIs. Increased risk of hepatotoxicity with ≥3 alcoholic drinks/day; avoid. β-blockers increase pressor effect of sympathomimetics. Antagonizes antihypertensives. Increased CNS effects with other CNS depressants.
Drowsiness, nervousness, dizziness, insomnia, anticholinergic effects, excitability in children; hepatotoxicity (overdosage).
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Fatigue Management Contributes to Effective Endometriosis Care
- Assessment of Low-Dose Aspirin As Chemoprevention in Type 2 Diabetes
- Treatment With Alemtuzumab May Frequently Induce Thyroid Dysfunction
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Risk for Hypoglycemia During Titration With Insulin Glargine 100 U/mL in T2D
- Trulicity Labeling Updated to Include Data on T2D Patients With CKD
- New Data Support Long-Term Cardiovascular Safety of Linagliptin in T2D
- Peer-Led Education Helps Physicians Save Time With EHRs
- As Immigration Policies Tighten, Physician Shortage Concerns Grow